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Resumo                  
RESUMO 
 
Doxiciclina (Dox) é um antimicrobiano pertencente à família das tetraciclinas com um 
amplo espectro de ação contra bactérias Gram-positivas e Gram-negativas. Além de suas 
propriedades antimicrobianas, Dox é atualmente empregada na periodontia como um 
modulador da resposta do hospedeiro (MRH), ao inibir a atividade da enzima 
metaloproteinase de matriz (MMP), a qual está relacionada ao processo de destruição 
tecidual. Neste contexto, este trabalho teve os seguintes objetivos: 1-determinar os 
parâmetros farmacocinéticos e integrar os índices PK/PD da Dox para o plasma, fluido 
gengival (FG) e saliva; 2-analisar os efeitos in vitro e in vivo da Dox sobre a 
osteoclastogênese com a finalidade de elucidar possíveis propriedades biológicas adicionais 
deste fármaco como MRH. Para a análise farmacocinética, 12 voluntários receberam dose 
oral única de 100 mg de Dox. Sangue, FG e saliva foram coletados em tempos pré-
determinados e a concentração da Dox nestes fluidos foi determinada por bioensaio. A 
análise dos principais índices PK/PD da Dox foi realizada considerando o CIM para P. 
gingivalis. Para o segundo objetivo, o efeito da Dox sobre os processos de diferenciação e 
ativação osteoclástica foi verificado, respectivamente, pela contagem de células TRAP+ 
multinucleadas geradas a partir de células precursoras estimuladas com sRANKL na 
presença ou ausência de Dox e pela análise das lacunas de reabsorção formadas por estas 
células, quando cultivadas sobre discos de dentina. In vivo, o efeito da Dox sobre a 
osteoclastogênese foi determinado através da indução deste processo em calvária de 
camundongo. Solução de sRANKL/LPS foi injetada na região da calvária e os animais 
receberam, por gavagem, Dox ou placebo diariamente. Após 10 dias, a calvária foi 
removida para análise histoquímica. Em acréscimo, a atividade da Dox sobre a expressão 
de genes responsáveis pelos processos de diferenciação e ativação osteoclástica foi 
analisada por RT-PCR. Durante os experimentos in vitro e in vivo, a produção e atividade 
da MMP foram verificadas através de Western-blot e Zimograma respectivamente. Os 
resultados demonstraram que as maiores concentrações de Dox foram observadas no 
plasma, seguido pelo FG e saliva. A análise dos índices PK/PD da Dox indicou que a dose 
de 100 mg foi insuficiente para se obter os valores ideais antimicrobianos preconizados na 
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literatura para os parâmetros ASC/CIM e Cmax/CIM. Os experimentos in vitro e in vivo 
sobre o efeito da Dox como MRH demonstraram que este fármaco inibiu os processos de 
diferenciação e ativação dos osteoclastos. Dox também modulou a expressão de proteínas 
diretamente relacionadas a osteoclastogênese, incluindo TRAP, Catepsina K e c-Myc. 
Finalmente, embora a síntese da MMP não tenha sido afetada, a atividade da MMP foi 
reduzida na presença de Dox. Portanto, os resultados do presente estudo sugerem que uma 
dose inicial maior do que 100 mg é necessária para alcançar o valor preconizado para 
ASC/CIM e Cmax/CIM, com a finalidade de se obter os melhores resultados clínicos 
antimicrobianos. A análise da Dox como MRH indicou que este fármaco pode atuar neste 
processo não somente pela sua capacidade de inativar a MMP, e sim, por apresentar a 
propriedade de inibir a diferenciação e ativação osteoclástica, incluindo a modulação de sua 
expressão gênica. 
 
 
Palavras-chave: Doxiciclina; farmacocinética; osteoclastos; RANKL. 
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ABSTRACT 
 
Doxycycline (Dox), a member of the tetracycline family, is an antimicrobial agent with a 
broad-spectrum of activity against Gram-positive and Gram-negative bacteria. In addition 
to its antimicrobial properties, Dox is used in the treatment of periodontal diseases as a host 
response modulator by inhibiting the activity of an important enzyme, matrix 
metalloproteinase (MMP), which is related to the process of tissue destruction. In this 
context, this study had the following aims: 1-to determine the pharmacokinetic parameters 
of Dox and to integrate the PK/PD indices for plasma, gingival crevicular fluid (GCF) and 
saliva; 2-to analyze the effects in vitro and in vivo of Dox on the osteoclastogenesis and on 
the osteoclast activation in order to elucidate additional biological properties of Dox on the 
host response modulation (HRM). Twelve volunteers received single oral administration of 
Dox (100 mg). Blood, GCF and saliva were collected and the concentrations were 
measured by bioassay technique. The PK/PD analyses were carried out using the MIC for 
P. gingivalis. For the second objective, the effect of Dox on the osteoclast differentiation 
and activation processes was determined, respectively, by the counting of TRAP+ 
multinuclear cells derived from osteoclast precursory cells sRANKL-stimulated in the 
presence or absence of Dox and by the analysis of the resorption areas formed by these 
cells when cultured on dentin discs. In vivo, Dox’s effect on the osteoclastogenesis was 
verified using the model of osteoclastogenesis induction in mouse calvaria. sRANKL/LPS 
was injected in the supra-calvaria area and the animals received Dox or placebo daily by 
gavage. After the experimental period of 10 days, the calvariae were removed for 
histochemistry analyses. In addition, the effect of Dox on the expression of genes related to 
the osteoclast differentiation and activation processes was carried out using RT-PCR 
technique. MMP production and activity were ensured during in vitro and in vivo 
experiments by Western-blot and Zymography, respectively. The results demonstrated that 
Dox achieved the highest concentration in the plasma, following by GCF and saliva. 
PK/PD analyses showed that the dose of 100 mg was insufficient to get the antimicrobial 
levels indicated in the literature for AUC/MIC and Cmax/MIC indices. In vitro and in vivo 
studies of Dox’s effects on the HRM demonstrated that this drug could inhibit the 
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osteoclast differentiation and activation process. Dox also showed an important property of 
down-regulation in the expression of proteins directly related to osteoclastogenesis, 
including TRAP, Cathepsin K and c-Myc. Finally, although Dox did not affect the 
expression of MMP protein, MMP activity was remarkably decreased by Dox. Therefore, 
the present study suggests that higher doses than 100 mg would be necessary to obtain 
effective antimicrobial levels and the effect of DOX on the HRM can be due to not only by 
MMP inhibition but also by the direct effect on RANKL-mediated osteoclast differentiation 
and activation, including its gene regulation.  
 
 
Key words: Doxycycline; pharmacokinetics; osteoclasts; RANKL. 
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Introdução                  
1. INTRODUÇÃO 
 
As doenças periodontais (DP) caracterizam-se como um processo inflamatório 
crônico que acomete os tecidos periodontais, levando a perda progressiva de inserção, com 
reabsorção óssea e migração apical do epitélio juncional, constituindo-se hoje como uma 
das principais causas de perda do elemento dentário (Dumitrescu et al., 2004). O tratamento 
mecânico (raspagem e aplainamento radicular) representa ainda hoje a forma mais eficaz 
para o controle desta patologia, porém, o reconhecimento de que as DP estão relacionadas 
com um grupo determinado de microrganismos provocou um aumento no interesse do uso 
de antimicrobianos como coadjuvante no tratamento destas doenças (Freeman et al., 1992).  
A terapia antimicrobiana visa reforçar o tratamento periodontal mecânico e dar 
suporte às defesas do hospedeiro, inibindo os microrganismos que permanecem viáveis 
após a terapia convencional. Porém, para que um fármaco seja efetivo no tratamento das 
DP, há a necessidade de níveis terapêuticos adequados no sítio da infecção. Atualmente, 
apenas alguns antibióticos possuem esta propriedade de se concentrar no fluido gengival 
(FG) e na saliva a partir de sua administração sistêmica, possibilitando assim, a sua 
indicação na periodontite (Pascale et al., 1986; Ramberg et al., 2001). 
A doxiciclina (C22H24N2O8.H2O) é um antibiótico pertencente ao grupo das 
tetraciclinas, produzida a partir de uma cultura mutante de Streptomyces aureofaciens 
(Amato Neto, 1994). Este fármaco tornou-se disponível comercialmente em 1962, sendo 
considerado uma tetraciclina de segunda geração ou de ação lenta por apresentar meia-vida 
mais prolongada, penetração tecidual mais intensa e maior atividade antimicrobiana (Cunha 
et al., 2000).  
A doxiciclina (Dox) é um antibiótico de amplo espectro, com atividade contra 
microrganismos Gram-positivos e Gram-negativos (Zhanel et al., 2004). Este 
antimicrobiano apresenta vantagens sobre os outros membros de seu grupo que incluem: 
baixa interferência com os alimentos durante o processo de absorção, índice reduzido de 
efeitos colaterais gastrointestinais e posologia conveniente, a qual favorece a aceitação do 
tratamento pelo paciente (Barza et al., 1975). 
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O mecanismo de ação da Dox assemelha-se a outras tetraciclinas. Em 
concentrações adequadas, este antibiótico exerce atividade bacteriostática por inibir a 
síntese protéica ao impedir a ligação do t-RNA à subunidade menor do ribossomo 
bacteriano - 30S. Em acréscimo, a Dox induz danos na membrana citoplasmática, 
promovendo assim, a perda de nucleotídeos e outros componentes celulares (Joshi & 
Miller, 1997). 
Na atualidade, diferentes métodos vêm sendo utilizados na tentativa de 
determinar a melhor posologia (dose/freqüência) antimicrobiana a ser empregada na prática 
clínica. De acordo com Van Bambeke & Tulkens (2001), o desenvolvimento de um 
esquema posológico efetivo inicia-se com o conhecimento das características químicas da 
molécula e culmina com a avaliação de sua atividade microbiológica e entendimento de 
suas propriedades farmacocinéticas (informações referentes aos processos de absorção, 
distribuição, metabolização e excreção) e farmacodinâmicas (dados sobre os prováveis 
mecanismos de ação e conhecimento da concentração inibitória mínima – CIM dos 
patógenos envolvidos). 
Neste contexto, diferentes autores preconizam a utilização de índices que 
correlacionam às propriedades farmacocinéticas (PK) e farmacodinâmicas (PD) com a 
finalidade de aperfeiçoar a posologia destes fármacos, obtendo assim, as melhores taxas de 
erradicação bacteriana com os menores níveis de resistência (Jacobs, 2001; Frimodt-Moller, 
2002). 
Dentre os principais índices que relacionam PK/PD dos agentes 
antimicrobianos, destacam-se a relação entre a área sob a curva e a CIM (ASC/CIM), e a 
concentração máxima e a CIM (Cmax/CIM) para os fármacos concentração-dependentes. 
Para os fármacos tempo-dependentes, o tempo em que a concentração excede o valor de 
CIM (T>CIM) constitui-se como o principal parâmetro a ser estudado (Barger et al., 2003).  
Além do aspecto microbiano, estudos atuais na área de Periodontia têm-se 
dirigido à elucidação do exato mecanismo da reabsorção óssea que ocorre na evolução das 
DP. Isto se deve ao fato de que embora a placa bacteriana seja considerada como o agente 
etiológico necessário para o início da DP e subseqüente degradação dos tecidos 
periodontais, a direta exposição aos componentes bacterianos isoladamente é responsável 
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apenas por uma proporção relativamente pequena da destruição periodontal 
(aproximadamente 20%). O maior componente da degradação das estruturas periodontais é 
o resultado da ativação da resposta imuno-inflamatória local do próprio hospedeiro (Salvi 
and Lang, 2005).  
O tecido ósseo é formado por células (osteoblastos e osteoclastos), minerais 
(cálcio e fósforo) e matriz orgânica (proteínas colágenas e não-colágenas). Os osteoblastos 
sintetizam e mineralizam a matriz protéica com cristais de hidroxiapatita, enquanto os 
osteoclastos promovem a reabsorção óssea, mantendo assim uma constante remodelação 
tecidual (Wittrant et al., 2003). Porém, diante de certos quadros patológicos, há um 
desequilíbrio em favor da reabsorção óssea, ocasionando assim a perda de sua matriz 
(Gravallese et al., 2001).  
Recentemente, uma nova proteína da família do Fator de Necrose Tumoral 
(TNF) denominada Ligante do Receptor Ativador do Fator NF-Kappa B (RANKL) tem 
sido relacionada com o processo de reabsorção óssea (Wittrant et al., 2003). RANKL é uma 
proteína de 317 aminoácidos, expressada por osteoblastos e células do estroma (Feng, 
2005). A interação de RANKL ao Receptor Ativador do Fator NF-Kappa B (RANK), 
presente nos osteoclastos e em seus precursores celulares, promovem a ativação de 
sinalizadores intracelulares, tais como, o Fator Nuclear de célula T ativada (NFAT), 
Ca2+/Calcineurin, NF-Kappa B e proteínas cinases ativadas por mitógenos (MAPK), 
induzindo assim, os processos de diferenciação e ativação dos osteoclastos (Jimi & Glosh, 
2005). 
De acordo com Teitelbaum et al. (2000), os osteoclastos são células 
multinucleadas, formadas pela fusão de progenitores mononucleares da família dos 
monócitos/macrófagos, sendo que a sua atividade pode ser avaliada por marcadores 
bioquímicos específicos. Um marcador clássico é representado pela Fosfatase Ácida 
Tartarato-Resistente (TRAP). TRAP é uma enzima lisossômica, que quando sintetizada 
pelos osteoclastos reflete a sua atividade, sendo estes denominados TRAP-Positivos 
(TRAP+) (Feng et al. 2005).  
Além deste papel de marcador biológico, a TRAP possui também uma 
importante função no processo de reabsorção óssea, devido a principal proteína da matriz 
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óssea, a osteonectina, constituir-se como um substrato para TRAP, e portanto, promovendo 
a degradação catabólica da matriz óssea (Oddie et al., 2000). Ek-Rylander et al. (1994) 
acrescentam que a TRAP também exerce uma atividade reguladora da adesão dos 
osteoclastos à superfície óssea. 
Outras importantes proteínas relacionadas com o processo de reabsorção óssea 
são representadas pela metaloproteinase de matriz (MMP) e pela Catepsina K. Esta última é 
responsável pela degradação dos cristais de hidroxiapatita, resultando na exposição do 
colágeno da matriz óssea. MMP compreende uma família de endopeptidases com atividade 
proteolítica, a qual pode liderar a destruição do tecido periodontal através da degradação do 
colágeno presente no tecido ósseo e gengival (Kadoglou & Liapis, 2004). Dentre as 
diferentes MMPs, a MMP-9 destaca-se por constituir-se como uma das mais abundantes no 
fluido gengival e por desempenhar um importante papel na atividade invasiva dos 
osteoclastos em pacientes com periodontite (Preshaw et al., 2005). 
Com estes conhecimentos, uma nova alternativa terapêutica vem sendo 
proposta na tentativa de controlar a progressão da DP, representada pelo processo de 
reabsorção óssea. Este “novo” grupo de fármacos foi denominado de moduladores da 
resposta do hospedeiro (Salvi & Lang, 2005). Neste contexto, Golub et al. (2001) destacam 
o uso da Dox em doses sub-antimicrobianas no controle da perda óssea alveolar, ao inibir a 
atividade da MMP e, consequentemente, a degradação do colágeno.  
Portanto, em decorrência da atividade da Dox sobre a microbiota periodontal, 
mas, principalmente de sua propriedade na modulação da perda óssea alveolar através da 
inibição da MMP, este fármaco vem se destacando atualmente como coadjuvante no 
tratamento periodontal, especialmente na periodontite crônica (Emingil et al., 2004; Lee et 
al., 2004; Novak et al., 2002). 
  Sendo assim, para um correto emprego da Dox na prática periodontal, torna-se 
necessário um conhecimento prévio das propriedades farmacocinéticas e 
farmacodinâmicas. Porém, a literatura indexada atual é escassa em trabalhos que 
correlacionam estes dois parâmetros (PK/PD) para este fármaco. Em acréscimo, embora o 
efeito da Dox na modulação da perda óssea seja atribuído principalmente a sua atividade de 
inibição da MMP, o exato mecanismo de ação da Dox sobre os processos de diferenciação 
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e ativação dos osteoclastos permanece ainda desconhecido. Portanto, este trabalho teve os 
seguintes objetivos: 1. Determinar os parâmetros farmacocinéticos e integrar os índices 
PK/PD da doxiciclina para o plasma, fluido gengival e saliva após administração oral de 
100 mg em 12 voluntários portadores de doença periodontal, otimizando assim, a sua 
posologia no tratamento das doenças periodontais; 2. Elucidar o efeito da Dox sobre os 
processos de diferenciação e ativação de osteoclastos mediada por RANKL, objetivando 
elucidar possíveis propriedades biológicas deste fármaco na modulação da resposta do 
hospedeiro em processos de destruição óssea. 
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2. CAPÍTULOS 
 
 Esta tese está baseada na Informação CCPG/002/06 (Anexo 1) e na aprovação 
pela Congregação da Faculdade de Odontologia de Piracicaba em sua 105a Reunião 
Ordinária em 17/12/2003, que regulamenta o formato alternativo para tese de Doutorado e 
permite a inserção de artigos científicos de autoria do candidato. 
 Assim sendo, esta tese é composta de dois capítulos contendo artigos que se 
encontram em fase de submissão ou submetidos para publicação em revistas científicas, 
conforme descrito a seguir: 
 
 
Capítulo 1 
 Artigo “Pharmacokinetics and PK/PD of doxycycline in plasma, gingival 
crevicular fluid and saliva after single oral dose” 
 Este artigo está em fase de submissão ao periódico: Journal Clinical of 
Periodontology. 
  
 
Capítulo 2 
 Artigo “Suppression of RANKL-mediated bone resorption by doxycycline” 
 Este artigo está submetido ao periódico: Bone (Anexo 4). 
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2.1 CAPÍTULO 1 
 
Pharmacokinetics and PK/PD of doxycycline in plasma, 
gingival crevicular fluid and saliva after single oral dose. 
 
Gilson Cesar Nobre Francoa, Cristiane de Cássia Bergamaschia, Luciana Aranha Bertoa 
Sinvaldo Baglieb, Francisco Carlos Groppoa, Pedro Luiz Rosalena
 
a Piracicaba Dental School, State University of Campinas (UNICAMP), Department of 
Pharmacology, Anesthesiology and Therapeutics, Piracicaba, SP, Brazil. 
b  State University of Ponta Grossa, Department of Pharmaceutical Sciences, Ponta Grossa, 
PR, Brazil. 
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Abstract 
The aim of this study was to investigate the pharmacokinetics (PK) and pharmacodynamics 
(PD) indices of doxycycline (Dox) in plasma, gingival crevicular fluid (GCF) and saliva in 
patients with periodontal disease. A single 100 mg oral dose of Dox was administered to 12 
volunteers of both genders (6 males and 6 females). Plasma, GCF and saliva were collected 
from pre-dose to 24 h. Dox concentration was quantified by a bioassay technique and PK 
parameters (Cmax; Tmax; T1/2; AUC0-24; AUC0-∞; Vd and Cl) were determined. PK/PD 
indices (T>MIC; AUC/MIC and Cmax/MIC) were estimated for P. gingivalis. The highest 
Dox concentration (Cmax) in plasma, GCF and saliva were 1.8 μg/mL at 2 h, 1.3 μg/mL at 2 
h and 0.4 μg/mL at 3 h, respectively. Dox also showed high volume of distribution (VD) 
indicating that Dox was able to penetrate into biological membranes and body tissues. 
Elimination half-life (T1/2) was 15.5 h in plasma, 21.2 h in GCF and 20.6 h in saliva. The 
Cmax/MIC and AUC/MIC ratios for P. gingivalis (considering a 0.25 μg/mL MIC) were 7.2 
and 86.8 h for plasma, 5.2 and 70.8 h for GCF, and 1.6 and 20 h for saliva, respectively. 
These results suggest that it could be necessary higher doses than 100 mg to obtain 
effective antimicrobial levels considering a 12 or 24 h dose interval. 
 
Keywords: Doxycyline; pharmacokinetic; pharmacodynamic; periodontal disease. 
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Introduction 
A successful periodontitis therapy requires a reduction in the number of 
bacteria responsible for periodontal infections (Kim et al., 2004). In this context, 
systemically administered antibiotics, such as doxycycline (a semi-synthetic tetracycline), 
have been widely used as adjuncts to the treatment of different forms of periodontitis (Feres 
et al., 1999; Needleman et al., 2001; Ramberg et al., 2001). 
Doxycycline (Dox) is a broad-spectrum antibiotic with activity against a wide 
range of gram-positive and gram-negative microorganisms (Zhanel et al., 2004). Dox 
shows several advantages over other tetracyclines, which include lower dosage and 
frequency, prolonged serum half-life, less effect of food during absorption and decreased 
gastrointestinal adverse-effects (Barza et al., 1975).  
Dox has a similar mechanism of action when compared with other tetracyclines. 
At clinical concentrations, Dox is bacteriostatic and inhibits the protein synthesis by 
binding to the 30S portion of bacterial ribosomes. This action blocks the entry of 
aminoacyl-transfer-RNA into the ribosome preventing the incorporation of amino acids into 
the peptide chains (Joshi & Miller, 1997).  
In addition to its antimicrobial properties, Dox has shown the ability to inhibit a 
group of enzymes called matrix metalloproteinases (MMPs) which are involved in soft- and 
hard-tissue destruction during pathological processes such as periodontitis, osteoarthritis 
and other diseases (Axisa et al., 2000). 
However, before selecting a drug for therapeutical use, the knowledge of its 
pharmacokinetic (PK) and pharmacodynamic (PD) properties is very important in clinical 
practice. This knowledge is necessary to achieve the beneficial effects with minimal 
adverse effects (Freeman et al., 1992; Cheymol, 2000).  
The PK characteristics are useful to determine and to understand how 
pharmacokinetics parameters, such as absorption, distribution, metabolization, and 
excretion, affect the drug regimen and its clinical use. The efficacy and adverse effects are 
also directly PK dependent, which consequently affect the drug acceptance by patients 
(Patsalos, 2004). 
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The PD parameters include the knowledge of the spectrum of activity, potency, 
the minimum inhibitory concentration (MIC), and the influence of time/concentration on 
drug effect (Frimodt-Moller, 2002).  
The integration of PK and PD indices (PK/PD) has been studied in order to 
optimize the effect of many antibiotics in vivo (Van Bambeke & Tulkens, 2001; Mouton, 
2002). The most PK/PD indices used to determine efficacy of “concentration-dependent” 
antibiotics are the ratio between the peak of blood (or other fluids) concentration and MIC 
(Cmax/MIC); and the ratio between area under concentration-time curve and MIC 
(AUC/MIC). In addition, the cumulative percentage of time (over a 24 h period) in which 
the drug concentration exceeds the MIC (T>MIC) is the most used PK/PD index for “time-
dependent” antibiotics (Barger et al., 2003).  
Nowadays, information on PK/PD for Dox is scarce in the literature. Therefore, 
the aim of the present study was to investigate the PK/PD indices of Dox in plasma, GCF 
and saliva in patients with periodontal disease.  
 
 
Material and Methods 
The protocol was approved by the ethical on research committee 
(FOP/UNICAMP, protocol #128/2004). All subjects provided written informed consent 
before their participation on study.  
 
Subject population 
The study population consisted of twelve healthy volunteers (6 male and 6 
female), ranging in age from 20 to 48 years (32.4 ± 8.97 years), weight from 50 to 84 kg 
(62.5 ± 10.88 kg) and height from 1.54 to 1.71 m (1.64 ± 0.06 m). The subjects did not 
present any disease except for at least two periodontal pockets ≥ 4 mm with attachment 
loss. The volunteers had not received neither systemic antibiotics within the last three 
months nor any other medication during the two weeks that preceded the study.  
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Antibiotic administration and clinical protocol 
Single oral dose of Dox (Vibramicina® - 100 mg) was administered to the 
volunteers in approximately 10 h of fasting conditions. 
Blood samples were collected via heparinized cannula at the following times: 
pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after Dox administration. Heparinized normal 
saline injection solution (1 mL) was flushed after each blood sampling. Samples were 
collected in a centrifuge sterile tube containing 10 % EDTA solution. Non-stimulated 
whole saliva (± 2 mL) was collect at the same periods of time. Blood and saliva samples 
were centrifuged (3000 rpm x 15 min) and the supernatants were stored at -70°C until the 
analyses.  
The gingival crevice fluid (GCF) was collected as described by Tenenbaum et 
al. (1993). Briefly, before the gingival fluid was sampled, cotton rolls were applied to 
prevent contamination of the sampling area with other oral fluids. The sample sites were 
gently dried and a standard filter paper (Periopaper, Oralflow Inc., Painview, NY, USA) 
were placed subgingivally for 30 seconds. The first GCF sample was discharged. Samples 
were obtained in duplicate at the same blood collection periods of time. All collected 
samples were stored in previous weighed eppendorf tubes. The volume of GCF was 
estimated by the difference between the weight of strips before and after fluid collection by 
using an analytical microbalance. The density of the GCF was considered 1.02 (Needleman 
et al., 2001). The samples were stored at -70°C until the analyses. 
 
Sample analyses (bioassay) 
A sensitive agar diffusion method, which is frequently used to measure small 
volumes of antibiotics, was carried out in order to determine the concentration of Dox in 
plasma, GCF and saliva (Gordon et al., 1981; Freeman et al., 1992; Sakellari et al., 2000). 
A strain of Bacillus cereus (ATCC11778) was incubated aerobically for 24 
hours at 37ºC. After this time, the broth was adjusted to an optical density of 0.15 at 550 
nm (approximately 108 cfu/mL) and seed in 150 mm plastic Petri dishes containing tryptic 
soy agar (TSA). 
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Sterilized stainless steel cylinders (5mm-diameter) with 60 μl samples (plasma 
or saliva) were placed in the Petri dishes previously seeded with B. cereus and then 
incubated at 37ºC for 16 hours. A calibration curve was obtained by known amounts of 
Dox (0.125, 0.25, 0.5, 1.0, 2.0 and 4.0 μg/mL) on antibiotic-free plasma or saliva by using 
the same technique described above. This calibration curve was used to calculate the 
plasmatic and salivary Dox concentrations on the samples. 
The concentration of Dox in the GCF was calculated according to Pascale et al., 
(1986). Briefly, standard curves were plotted by using the inhibition area surrounding the 
Periopaper and known absolute amounts of antibiotics (0.5, 1, 2, 4 and 10 pg). The 
concentration was calculated by the proportion between absolute amount of Dox and the 
GCF volume on each Periopaper. 
 
Pharmacokinetics and statistical analysis  
In this study, the following Dox PK-parameters were obtained: 
- Cmax: the highest concentration observed during the 24-hour study period;  
- Tmax: the time at which Cmax occurred;  
- T1/2: half-life elimination. The time required for the amount of a substance in a biological 
system to be reduced to one half of its value by biological processes.  
- AUC0-24: the area under the concentration-time curve from baseline to 24 h;  
- AUC0-∞: the area under the concentration-time curve from baseline to 24 h plus the 
residual area; 
- CL: clearance;  
- VD: volume of distribution.  
These parameters were determined by using a computer software (PK 
Solutions, Non-compartmental Pharmacokinetics Data Analysis Excel Template, 2001, 
Summit Research Services, Montrose, CO, USA). 
In order to study the Dox PK/PD indices, it was considered a MIC value of 0.25 
μg/mL of P. gingivalis, which is one of the most common pathogens for periodontal disease 
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(Chang et al., 1994; Nichols & Rojanasomsith, 2006). The following PK/PD indices were 
obtained (Toutain et al., 2002; Barger et al., 2003): 
- Cmax/MIC: the peak level divided by the MIC; 
- AUC0-24/MIC: the area under the concentration-time curve over 24 h divided by the MIC; 
- T>MIC: the time over a 24 h period in that the drug concentration exceeds the MIC. It is 
obtained by simple inspection of the simulated curve and generally expressed as a 
percentage of the dosage interval. 
 The Figure 1 represents a scheme of the mainly PK/PD indices. 
MIC
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Figure 1. A representative scheme of the mainly PK/PD indices used in the therapeutics 
(Cmax/MIC; AUC/MIC and T>MIC).  
 
 
Results 
Dox PK in plasma, GCF and saliva 
The bioassay method was sensitive to quantify Dox in plasma (limit of 
quantification=0.125 µg/mL, R2=0.991); GCF (limit of quantification=0.5 pg, R2=0.986); 
and saliva (limit of quantification=0.125 µg/mL, R2=0.993). Antimicrobial activity was not 
detected in any of the samples of baseline time (pre-dose). The mean (± SD) of plasma, 
GCF and saliva are shown in Table 1 and illustrated in Figure 2. 
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Table 1. Average concentration (± SD) in plasma, GCF and saliva following administration 
of a single 100 mg oral dose of Dox (12 volunteers). 
 
Time (h) Plasma (µg/mL) GCF (µg/mL) Saliva (µg/mL) 
0 0.000 (± 0.00) 0.000 (± 0.00) 0.000 (± 0.00) 
0.5 0.841 (± 0.57) 0.096 (± 0.11) 0.094 (± 0.08) 
1 1.293 (± 0.68) 0.642 (± 0.51) 0.218 (±0.10) 
2 1.772 (± 0.90) 1.337 (± 0.94) 0.352 (± 0.10) 
3 1.405 (± 0.49) 1.066 (± 0.55) 0.365 (± 0.13) 
4 1.140 (± 0.41) 1.001 (± 0.36) 0.272 (± 0.10) 
6 1.135 (± 0.47) 1.032 (± 0.48) 0.269 (± 0.13) 
8 0.968 (± 0.38) 0.972 (± 0.46) 0.239 (± 0.07) 
12 0.890 (± 0.31) 0.692 (± 0.32) 0.197 (± 0.06) 
24 0.520 (± 0.19) 0.467 (± 0.25) 0.132 (± 0.07) 
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Figure 2. Concentration-time curve of Dox in plasma, GCF and saliva obtained from 12 
volunteers after single oral administration (100 mg). 
Dox was found 30 minutes following oral administration in all body fluid 
analyzed. Cmax was achieved in plasma (1.8 μg/mL) after 2 hours, GCF (1.3 μg/mL) after 2 
hours and saliva (0.4 μg/mL) after 3 h.  
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Dox also showed a high VD, indicating the likelihood of good penetration of 
biological membranes and tissue distribution. The Dox PK-parameters in the different body 
fluids are presented in Table 2. 
 
Table 2. Dox PK-parameters in plasma, GCF and saliva after single 100 mg oral 
administration (12 volunteers). 
 
 Tmax (h) 
Cmax 
(μg/mL) 
T1/2 
(h) 
Cl 
(L/h/70kg) 
Vd 
(L/70kg) 
AUC0-24 
(μg.h/mL) 
AUC0-∞ 
(μg.h/mL) 
Plasma 2.0 1.8 15.5 3.4 75.1 21.7 33.3 
GCF 2.0 1.3 21.2 3.5 106.9 17.7 32.1 
Saliva 3.0 0.4 20.6 12.6 375.0 5.0 8.9 
 
 
PK/PD indices 
 Plasma showed the highest values for all PK/PD indices. Cmax/MIC and 
AUC/MIC ratios were 7.2 and 86.8, respectively considering plasma; 5.2 and 70.8, 
respectively considering GCF; and 1.6 and 20, respectively considering saliva.  
The time in that concentration of Dox in plasma, GCF and saliva exceeded the 
P. gingivalis MIC (T>MIC) were approximately 98%, 96% and 25%, respectively. 
 
 
Discussion 
The knowledge of the PK/PD properties is important to select the correct dose 
and dosage regimen. It is also important to minimize the risk to develop microbial 
resistance during the treatment (Bonapace, 2002; Frimodt-Moller, 2002).  
Dox is readily and almost completely absorbed (95%) from the gastro-intestinal 
tract (Cunha, 1999). In the present study, Dox showed a relative high half-life and VD 
values in the three compartments studied. According to Joshi & Miller (1997), this relative 
high VD of Dox could be explained by its lipophilic nature allowing an excellent tissue 
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penetration. In addition, Dox is a well-known time-dependent antibiotic that produces 
moderate to prolonged post-antibiotic effect (PAE) against the majority of susceptible 
microorganisms (Van Bambeke & Tulkens, 2001; Craig, 2003). Therefore, the Dox time 
intervals could be significantly enlarged when compared to other antibiotics with little or 
no PAE. These data together indicate that it is possible to maintain effective antimicrobial 
levels during a long period and, thus, even once-daily administration could be very 
acceptable.   
Although Dox is considered time-dependent antibiotic, it has been shown that 
the T>MIC parameter is not that important due to its PAE and PK properties. Thus, the 
goal of therapy considering Dox is to optimize the amount of drug, being the AUC/MIC 
index more important to determine its efficacy. 
In general, the PK/PD ratios has been considered as 100 to 125 h for AUC/MIC 
and 8 to 12 for Cmax/MIC considering concentration-dependent antibiotics and 60% for 
T>MIC considering time-dependent antibiotics (Mouton, 2002; Barger et al., 2003). The 
present study indicated that the oral administration of 100 mg of Dox was satisfactory for 
T>MIC parameter in both plasma and GCF but the values of AUC/MIC and Cmax/MIC 
were lower than those indicated in the literature (100 – 125 for AUC/MIC and 8 to 12 for 
Cmax/MIC) for all compartment studied. Thus, in order to improve these indices, an initial 
dose higher than 100 mg should be used. This procedure could increase the Dox 
concentration in the body fluids and consequently the AUC and Cmax values. There are very 
few side effects attributed to Dox and an increase on the clinical dose could be safe. 
A previous study showed a higher concentration of Dox in GCF than plasma 
(Pascale et al., 1986). However, in the present study, we found plasma levels 40% higher 
than GCF levels. Probably, this difference occurred because we used a single 
administration rather than multiple administrations. According to Golub et al. (1994), Dox 
is able to bind to the dental-root surface, favoring its slow release, while it keeps the 
antimicrobial activity, and therefore, it could maintain increased GCF concentrations, 
especially after multiple doses. However, we could not find in the present study higher 
levels of Dox in GCF in comparison to plasma. Probably, the methodology used to collect 
the GCF could be responsible for these differences. 
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Sakellari et al. (2000) observed that this high GCF levels could be related to 
methodology errors. Many studies used long sampling times (2 minutes or more) and, in 
this case, it is possible that the samples could have concentrated on the filter paper strips by 
evaporation. In order to minimize this effect, the GCF samples in the present study were 
collected in just 30 seconds. This sampling short time was shown to be adequate to collect 
sufficient fluid for the PK analyses by bioassay method and it minimized the evaporation 
since the strips were kept on sealed mini tubes. 
In conclusion, the present study suggests that it could be necessary higher doses 
than 100 mg to improve the antimicrobial clinical outcomes considering AUC/MIC index.  
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Abstract 
Inflammatory bone resorption occurs in the context of chronic infectious diseases, such as 
periodontal disease, septic arthritis and osteomyelitis. In such infectious bone loss lesions, 
receptor activator of NF-kappaB ligand (RANKL) plays a key role in the induction of 
osteoclast differentiation and activation. In the present study, we found that doxycycline 
(Dox), a semi-synthetic tetracycline antibiotic, was able to suppress RANKL-mediated 
bone resorption, both in vitro and in vivo. Dox inhibited RANKL-mediated osteoclast 
differentiation from both RAW264.7 cells and mouse bone marrow cells. Dox also 
inhibited matrix metalloproteinase-9 (MMP-9) activity in RANKL-stimulated RAW264.7 
cells, while the total protein level of MMP-9 up-regulated by RANKL stimulation was not 
affected by the presence of Dox. Importantly, systemic Dox administration did not alter the 
viability of RAW264.7 cells as well as bone marrow cells, irrespective of RANKL 
stimulation, indicating that the reduction of osteoclastogenesis was not due to the loss of 
cell number as a result of Dox toxicity. Dox did not affect the RANKL-mediated 
phosphorylation of p38-, ERK- or JNK-Mitogen-Activated Protein Kinase (MAPK), key 
signal transduction molecules in osteoclast differentiation and activation. Focused DNA 
array and RT-PCR analyses revealed that Dox suppresses the mRNA expression of 
osteoclast differentiation/activation c-Myc promoter. Systemic Dox administration also 
suppressed in vivo induction of TRAP-positive osteoclasts, which were induced in calvaria 
tissues by sRANKL/LPS injection, without affecting systemic bone mineral density 
(BMD). The suppression function of Dox on MMP-9 enzyme activity has been previously 
demonstrated. More important to the present study, however, the results noted above 
indicated that Dox also suppresses RANKL-mediated bone resorption by interrupting the 
induction of osteoclast differentiation in association with the inhibition of mRNA 
expression for c-Myc, TRAP and cathepsin K. In conclusion, the present study indicated 
that the efficacy of Dox in the amelioration of inflammatory bone loss lesion seems to 
involve novel bio-effects of Dox which inhibit RANKL-mediated osteoclastogenesis, in 
addition to its previously known effects as an antibiotic and as an MMP suppressor.  
 
Keywords: Doxycycline therapeutics, RANKL, Osteoclasts, MMP-9, c-Myc. 
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Introduction 
Bone resorption is facilitated by osteoclasts, multinucleated giant cells, which 
are derived from mononuclear precursor cells present in bone marrow. These cells not only 
play an important role in the maintenance of homeostatic bone remodeling, but they also 
cause pathological bone loss in several diseases, including rheumatoid arthritis, 
osteomyelitis, periodontal disease and postmenopausal osteoporosis (9, 39).  
Differentiation and activation of osteoclast cells depend on the stimulation of 
osteoclast precursor cells with receptor activator of nuclear factor ligand (RANKL) and its 
permissive cytokine M-CSF (2). RANKL is a member of the tumor necrosis factor family 
and is expressed by osteoblast/stromal cells, as well as by activated lymphocytes (2, 14, 32, 
37, 38), under regulation of a complex system of co-stimulatory signals generated by other 
cell surface receptors (16). In addition to RANKL, tumor necrosis factor alpha (TNF-α) 
was also found to stimulate osteoclastogenesis in an RANKL-dependent or -independent 
manner (15, 18). 
Host-derived enzymes regulate the remodeling of extracellular matrix proteins 
which are important components in both soft tissue and bone. A group of enzymes, called 
matrix metalloproteinases (MMPs), is intimately involved in the degradation of 
extracellular matrixes, and 26 enzymes are currently known to belong to the MMP family 
(22). The importance of MMPs, especially MMP-9 (gelatinase B), derives from their 
involvement in the physiologic and pathologic decomposition of hard tissue, particularly 
bone, which is composed of both extracellular matrix proteins and calcified mineral 
compounds. Originally, MMP-9 was found to be secreted by macrophages and neutrophils, 
as these cells migrate towards the inflamed tissues by a process of degrading the matrix 
components in the basal membrane (6). Later, MMP-9 was demonstrated to be involved in 
the invasive activity of osteoclasts by causing the degradation of extracellular matrix 
collagens (12, 29, 43). It is true that MMP-9 (gelatinase B) is recognized as the most 
abundant gelatinolytic MMP in mature osteoclasts (25, 44). However, in spite of previously 
accumulated knowledge, the specific mechanism underlying matrix metalloproteinase 
inhibitors (MMPIs)-mediated inhibition of bone resorption is yet to be elucidated, 
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specifically whether MMPIs inhibit bone loss solely by suppressing the MMP activities 
without affecting the differentiation or activation of osteoclasts. 
MMPIs can inhibit alveolar bone loss induced by local LPS injection in a rat 
model of experimental periodontal disease (24). Among clinically applied MMPIs, the use 
of doxycycline (Dox), a semi-synthetic tetracycline antibiotic, has been growing in clinical 
practice for a range of diseases (28). This essentially results from its robust inhibitory 
effects on MMPs, especially MMP-9 (26, 30). Based on the clinical efficacy of Dox, as 
demonstrated in its effects on rheumatoid arthritis and periodontal disease, which both 
involve inflammatory bone loss, the non-antimicrobial effects of Dox and its derivatives are 
therefore indicated as having anti-inflammatory action that involves inhibition of MMPs (8, 
28). The inhibitory effect of Dox on bone loss has been attributed to its ability to inhibit 
MMP-9 activity and to possibly suppress osteoclast differentiation (8, 27). Still, the precise 
mechanism underlying Dox-mediated bone loss inhibition is unclear. Most importantly, 
although it has become apparent that RANKL plays a key role in the induction of osteoclast 
differentiation and activation of mature osteoclasts, the effects of Dox on the RANKL-
dependent osteoclast differentiation mechanism are totally unknown. To address these 
questions, the present study investigated the influences of Dox on RANKL-mediated 
osteoclastogenesis, both in vitro and in vivo, that result in bone resorption. 
 
 
Materials and Methods 
Antibiotics 
Doxycycline (Dox), Amoxicillin (Amo), Vancomycin (Van), Bacitracin (Bac), 
Spectinomycin (Spc) and Gentamicin (Gen) used in this study were purchased from Sigma-
Aldrich Corp., St. Louis, MO, USA.  
 
In vitro osteoclast differentiation and cellular viability assays 
A murine macrophage cell line (RAW264.7) (5x103 cells/well) and BALB/c 
mouse bone marrow cells (2x105 cells/well) were stimulated with 50 ng/ml of soluble 
RANKL (sRANKL, mouse recombinant, PeproTech Inc., Rocky Hill, NJ, USA) in α-MEM 
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supplemented with 15% Fetal bovine serum (FBS) and containing 100 units/ml penicillin 
and 10 μg/ml streptomycin (α-MEM complete medium). For the bone marrow culture, M-
CSF (10 ng/ml, PeproTech) was supplemented with sRANKL. The following antibiotics 
were additionally applied to this α-MEM complete medium: Dox (0.2 and 2 μg/mL); Amo 
(0.5 and 5 μg/mL); Van (2 and 20 μg/mL); Bac (0.2 and 2 μg/mL); Spc (10 and 100 μg/mL) 
and Gen (0.5 and 5 μg/mL). The cells were incubated for 6 days at 37°C in 5% CO2 
atmosphere. The half volume of culture supernatant was replaced with fresh medium 
containing sRANKL (and M-CSF for bone marrow), in the presence or absence of 
antibiotics, every three days. After the appropriate incubation time (RAW264.7 cells - 6 
days; bone marrow cells - 8 days), the medium and nonadherent cells were removed by 
rinsing with phosphate buffered saline solution (PBS). The remaining cells in each well 
were fixed with formaldehyde saline and subsequently stained by tartrate-resistant acid 
phosphatase (TRAP-staining assay) (13, 14, 40). Osteoclast-like cells with three or more 
nuclei were identified as TRAP-positive (TRAP+) cells.  
In addition, the effect of antibiotics on the viability of RAW264.7 cells and 
bone marrow cells was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl-
tetrazolium bromide (MTT) assay. After incubation of cultured cells in 96-well culture 
plates with MTT for 4 hours, the blue formazan that developed in the viable cells was 
dissolved by isopropanol, and the intensity of dissolved blue formazan was measured using 
(OD at 575 nm). The production of formazan from the treated and control (non-treated) 
cells was then compared. 
 
Pit formation assay 
In order to determine the bone resorption activity by mature osteoclasts, a pit 
formation assay was carried out using dentin discs (diameter = 5 mm; ALPCO Diagnostics, 
Windham, NH, USA) (16). The RAW264.7 cells (5x103 cell/well) were cultured on dentin 
discs in 96-well culture plates for 6 days with sRANKL (50 ng/mL), with or without Dox 
(2 μg/mL). The half portion of culture medium was replaced with fresh medium containing 
respective additive every three days. After incubation, the cells were removed by washing 
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with 10% sodium hypochlorite, and the dentin discs were then stained by a 0.5% Toluidine 
Blue solution (14).  
 
Gelatin Zymogram 
For the measurement of gelatinase activity, a gelatin zymography was utilized. 
The amount of total protein in each sample was measured using Quant-iTTM protein assay 
kit (Invitrogen, Carlsbad, CA, USA). Based on the results of Quant-iTTM protein 
measurement, an equal amount of sample protein was separated by electrophoresis in 10% 
Tris-Glycine zymogram gelatin gel (Invitrogen) under non-reducing conditions. After 
renaturing the proteins separated in the gel, the zymogram gel was developed in 
Developing Buffer supplied by the manufacturer (Invitrogen). Subsequently, the developed 
gelatin gel was stained with colloidal blue stain (Invitrogen), allowing the proteases to be 
visualized as clear bands on the gelatin gel. 
 
Western blot analysis 
Total proteins were extracted from the cultured cells with lysis buffer-A that 
contains 25 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 
0.1% SDS, 1% NP-40, 1 mM PMSF,  protease inhibitor cocktail (Sigma) and phosphatase 
inhibitor I and II (Sigma) (106 cells/100 ul of lysis buffer). Insoluble cellular components 
were removed by centrifugation at 10,000 × g at 4°C for 20 min. The cell lysates were 
further dissolved in SDS-PAGE loading buffer (Invitrogen, Carlsbad, CA, USA) containing 
2-mercaptoethanol. After boiling for 10 min, the cell lysates were subjected to SDS-PAGE, 
and the proteins separated in the gel were blotted onto a nitrocellulose membrane. After 
blocking with 5% skim milk, the membrane was incubated with specific primary antibodies 
to MMP-9 (goat polyclonal, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and to α-
Tubulin (mouse monoclonal, clone B-7, Santa Cruz), followed by incubation with 
peroxidase-conjugated rabbit anti-goat IgG and peroxidase-conjugated goat polyclonal anti-
mouse IgG (Sigma), respectively. The bands recognized by the specific antibody were 
visualized using the chemiluminecsence-based ECLTM system (Amersham Biosciences, 
Piscataway, NJ) and exposed to an X-ray film (Eastman Kodak, Rochester, NY). In order to 
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investigate the effect of Dox on mitogen-activated protein kinase (MAPK) signaling 
pathways, phosphorylations of p38, ERK and JNK induced in RAW264.7 cells upon 
stimulation with sRANKL were examined using Western blot. 
 
Reverse transcriptase-polymerase chain reaction (RT-PCR) 
Total RNA was extracted from cultured cells by using RNA-Bee (TEL-TEST, 
Inc., Friendswood, TX). Complementary DNA (cDNA) was synthesized from the freshly 
isolated total RNA (100-500 ng) using SuperScriptTM-II transcriptase (Invitrogen) following 
the manufacturer's instructions. The resulting cDNA was reacted and amplified with 
specific PCR primers in the presence of Taq polymerase (Hot Start Taq, Qiagen, Valencia, 
CA). The primer sequences are as follows: TRAP, 5'-
ACACAGTGATGCTGTGTGGCAACTC and 3'-
CCAGAGGCTTCCACATATATGATGG (26); cathepsin K, 5'-
CTGAAGATGCTTTCCCATATGTGGG and 3'- GCAGGCGTTGTTCTTATTCCGAGC 
(26); c-Myc, 5’-ACGTCTCCACTCACCAGCACAACT and 3’-
GCTCCTCCTCGAGTTAGGTCAGTT; β-actin, 5'-GCTTCCTGGGCATGGAATCCTG 
and 3'-GGAGGAGCAACAATCTTGATCTTC. The amplified PCR products were 
separated by electrophoresis in 1.5% agarose gels. The PCR products in the gels were 
visualized by SYBR safeTM (Invitrogen) and scanned using AlphaImager® (San Leandro, 
CA). 
 
In vivo bone resorption assay - Induction of osteoclasts in mouse calvaria tissue  
In vivo, the effect of Dox on MMP activity and on osteoclastogenesis was 
evaluated using mouse calvaria (21). BALB/c mice (6-week-old males – 5 animals/group) 
received a supra-calvaria injection (50 μl/site/day) of a combination of sRANKL (5 μg/ml) 
and LPS (500 μg/ml), or control PBS, for three consecutive days. The animals were treated 
with daily administration of Dox (30 mg/kg), or PBS by gavage, for 10 days. Zymography 
and TRAP staining were carried out on the calvaria tissues removed from the killed animals 
on Day 10. All experimental procedures using mice were approved by the Institutional 
Animal Care and Use Committee (IACUC) at The Forsyth Institute. 
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A half portion of calvaria was homogenized in lysis buffer-B (0.1% SDS, 1% 
NP-40, 1% Triton X-100, 25 mM Tris and 150 mM NaCl) without protease inhibitors. 
After adjusting the concentration of protein using the Quant-iTTM protein assay kit, calvaria 
tissue homogenates were subjected to gelatin gel zymography and Western blot analyses 
for MMP-9 and α-tubulin, as previously described. 
The calvariae were fixed and decalcified in 10% EDTA solution for 21 days. 
These calvariae were embedded in Tissue-Tek (Sakura, Torrance, CA), and coronal 
sections (8 μm in thickness) were obtained using a cryostat. The sections were stained for 
TRAP, and the nuclei were counter-stained with methyl green. 
 
Measurement of TRAP activity in the calvaria homogenates 
The calvaria tissue was homogenized in the lysis buffer-B. The samples and 
standard recombinant TRAP were reacted with p-nitro-phenol-phosphate in 150 mM 
tartrate buffer (pH 5.5) supplemented with 1 mM MgCl2. After 2 h of incubation at 37°C, 
the reaction was stopped by the addition of 2N NaOH. The absorbance at 405 nm was 
measured by a spectrophotometer. This assay system only showed specificity to TRAP, but 
did not show reactivity to alkaline phosphatase (ALP). Consequently, ALP activity was 
determined by the parallel assay using ALP (Sigma) as a control group, which did not show 
color development under the conditions described above. 
 
Effect of Dox on bone mineral density (BMD) – in vivo assay 
BALB/c mice (8-week-old males, 5 mice/group) were treated with either Dox 
(30mg/kg/day in water solution) or with control water for 30 days (p.o. every single day). 
Afterwards, the animals were killed, and the measurement of BMD (g/cm2) of whole body 
and femur was performed using PIXImusTM bone mineral densitometer (Lunar Corp., 
Madison, WI).  
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Statistical analysis 
The results were expressed as mean ± standard deviations (SD). Statistical 
differences between the mean values of control and experimental groups were analyzed by 
using ANOVA or Student’s t test at a significance level of 5%. 
 
 
Results 
Dox suppressed RANKL-mediated osteoclast differentiation 
To examine the effects of Dox on RANKL-mediated osteoclastogenesis, 
RAW264.7 cells were stimulated with sRANKL in the presence or absence of different 
antibiotics (Figure 1 A). Compared to the number of TRAP+ multinuclear cells induced in 
the positive control of RAW264.7 cells, which were stimulated with sRANKL alone, Dox 
concentration at both 0.2 and 2 μg/ml significantly reduced the number of TRAP+ 
multinuclear cells. The other antibiotics, including Amo, Van, Bac, Spc and Gen, did not 
show any suppressive effect on the RANKL-mediated osteoclastogenesis induced in 
RAW264.7 cells.  
Dox treatment also inhibited the induction of TRAP+ multinuclear cells in bone 
marrow cells upon sRANKL stimulation in the presence of M-CSF. Since Dox also 
inhibited the induction of TRAP+ multinuclear cells from bone marrow cells stimulated 
with sRANKL alone, Dox appeared to inhibit the RANKL-mediated differentiation of both 
osteoclast precursor cells, as well as intermediately differentiated pre-osteoclasts (Figure 
1B). The images of TRAP staining of both RAW264.7 cells and bone marrow cells 
stimulated with sRANKL in the presence or absence of Dox are shown in Figure 2 (A-C, 
RAW264.7 cells; and D-F, bone marrow cells). Importantly, the increased number of 
TRAP+ mononuclear cells was observed in both RAW264.7 cells, as well as bone marrow 
cells, which were stimulated with sRANKL in the presence of Dox (Fig. 2 C and F), 
suggesting that Dox allowed osteoclast precursor cells to differentiate to TRAP+ pre-
osteoclast cells.    
The bone resorption activity of mature osteoclasts induced in RANKL-
stimulated RAW264.7 cells was analyzed on dentin slice surfaces (Fig. 2, G-H). 
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Stimulation of RAW264.7 cells with sRANKL remarkably increased decalcified areas on 
the dentin discs (H) compared to the control non-stimulated RAW264.7 cells (G), which 
showed few or no resorption pits. The addition of Dox to the culture of sRANKL-
stimulated RAW264.7 cells inhibited the formation of resorption pits on dentin discs (I). 
These results indicated that Dox not only suppresses RANKL-mediated osteoclast 
differentiation, but also inhibits bone resorption activity.  
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Fig. 1. Effects of antibiotics on the RANKL-dependent induction of TRAP+ 
multinuclear cells. A) RAW264.7 cells were stimulated with sRANKL (50 ng/ml) for 6 
days in the presence or absence of antibiotics shown in the figure. B) BALB/c mouse bone 
marrow cells (6-week-old) were cultured with sRANKL and/or M-CSF in the presence or 
absence of two different doses of Dox (0.2 and 2 μg/ml) for 8 days. A half portion of 
culture medium was replaced every three days. After respective periods of incubation, the 
cells were fixed with formalin and subjected to TRAP staining. TRAP+ cells with nuclei 
equal to, or exceeding, three were counted. Data represent mean ± SD of triplicate cultures. 
*Significantly lower than sRANKL or sRANKL+M-CSF stimulation by Student’s t test 
(p<0.05). 
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Fig. 2. Microscopic analyses of the effects of Dox on the appearance of osteoclasts 
induced by sRANKL and pit formation assay to determine the effect of Dox on the 
osteoclasts’ bone resorption function (Magnification, 20x). RAW264.7 cells (A-C) and 
bone marrow cells (D-F) were stimulated with or without sRANKL in the presence or 
absence of Dox (2 μg/ml), following the same incubation protocol described in Fig. 1. After 
respective periods of incubation (RAW264.7 cells - 6 days; bone marrow cells - 8 days), 
the cells were fixed and stained for TRAP, followed by nuclear staining with methyl green.  
Pit formation assay (G-H) was carried out on the dentin slices using RAW264.7 cells. After 
incubation for 6 days, the cells were removed by washing with 10% sodium hypochlorite, 
and the dentin discs were stained by a 0.5% Toluidine Blue solution. The arrows (H) 
indicate the decalcified pits formed by activated mature osteoclasts.  
 
 
In order to evaluate whether the suppression effects of Dox on RANKL-
mediated osteoclastogenesis is due to its toxicity, MTT assay was carried out on the 
RAW264.7 cells and bone marrow cells stimulated with sRANKL in the presence or 
absence of Dox (Fig. 3). Dox did not decrease the viability of either RAW264.7 cells or 
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bone marrow cell cultures, irrespective of the presence of sRANKL. These results indicated 
that the suppression of RANKL-mediated osteoclast differentiation/activation by Dox was 
not due to the presence of any Dox toxicity. 
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Fig. 3. MTT assay for toxic influence of Dox on sRANKL-stimulated RAW264.7 cells 
and bone marrow cells. MTT testing was carried out to evaluate the effect of Dox and 
sRANKL on cell viability. A) RAW264.7 cells were cultured with or without sRANKL (50 
ng/ml) in the presence or absence of Dox for 24 hours. B) Bone marrow cells were cultured 
with or without sRANKL (50 ng/ml) and/or M-CSF (10 ng/ml). All groups of cells were 
subjected to MTT assay, and relative viability of cells in each well was expressed by 
OD575 of dissolved formazan. The Dox treatment groups did not show any statistically 
significant difference compared to the control non-treatment groups. Solid or open columns 
indicate “with” or “without Dox treatment”, respectively. 
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Dox suppressed MMP-9 gelatinase activity in the RANKL-stimulated RAW264.7 cells 
The non-antibiotic property of Dox is implicated in the inhibition of MMP 
activities, especially MMP-9 (4). Therefore, the influence of Dox on the MMP-9 activity of 
RAW264.7 cells stimulated by sRANKL was analyzed in gelatin gel zymography (Fig. 4 
A). Stimulation of RAW264.7 cells with recombinant sRANKL induced an up-regulation 
of MMP-9 activity, whereas Dox nearly abolished this up-regulation (Fig. 4 A). 
The influence of Dox on MMP-9 protein expression in RAW264.7 cells was 
examined by Western blot (Fig. 4 B). This analysis demonstrated that sRANKL stimulation 
up-regulated MMP-9 protein expression. More importantly, the addition of Dox to the 
RAW264.7 cell culture did not affect sRANKL-induced up-regulation of MMP-9 protein 
expression in the RAW264.7 cells. These results indicated that Dox suppressed MMP-9 
activity, but not MMP-9 protein expression (Fig. 4). In summary, stimulation of RAW264.7 
cells with sRANKL up-regulated the amount of MMP-9 protein, irrespective of the 
presence of Dox, whereas MMP-9 activity was blocked by Dox. 
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Fig. 4. Gelatin gel zymography and Western blot analyses for the MMP-9 expressed in 
RAW264.7 cells. RAW264.7 cells were incubated with sRANKL in the presence or 
absence of Dox for 24 hours. The amount of protein isolated from harvested cells was 
adjusted and subjected to gelatin gel zymography (A) and Western blot for MMP-9 and α-
Tubulin (B). Mature MMP-9 (MW 86 kD) is indicated by arrow shown in the zymogram 
gel. 
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Dox administration “in vivo” suppressed osteoclast differentiation and MMP-9 activity 
In order to examine the effects of Dox on in vivo osteoclast differentiation, 
osteoclastogenesis was induced by supra-calvaria injections with a mixture of sRANKL 
and LPS. Since bacterial inflammatory components, such as LPS, are present in the context 
of chronic infectious diseases with bone resorption, LPS was applied together with 
sRANKL. Ten days after sRANKL/LPS injection, animals were sacrificed, and decalcified 
calvaria tissues were analyzed by histochemistry using TRAP staining. The sRANKL/LPS 
injection induced a remarkably increase in the number of TRAP+ osteoclast-like cells in the 
calvaria bone lacunae compared to the control mice, which received placebo (PBS) 
injection (Fig. 5 A, control PBS; B, sRANKL+LPS injection), whereas systemic 
administration of Dox reduced the induction of TRAP+ osteoclast-like cells in the calvaria 
tissues receiving sRANKL/LPS (Fig. 5 C). The injection of sRANKL alone also induced 
relatively fewer TRAP+ osteoclast-like cells in calvaria than did the sRANKL/LPS 
injection (not shown), indicating that inflammatory stimulation caused by LPS augments 
RANKL-mediated osteoclastogenesis in calvaria, but that, significantly, Dox can inhibit the 
RANKL-mediated osteoclastogenesis in the context of inflammation.  
The TRAP enzyme activities measured in the homogenates of calvaria tissues 
also demonstrated a similar trend in the histochemical evaluation (Fig. 5 D). In this 
analysis, the sRANKL/LPS injection significantly up-regulated the TRAP activities in the 
calvaria homogenates compared to the control PBS-injected calvaria tissues, while Dox 
administration abrogated such TRAP activities induced by sRANKL/LPS injection (Fig. 5 
D).  
The gelatinase activity of MMP-9 in the calvaria tissue homogenates was also 
examined using Zymography (Fig. 5 E). Dox treatment abrogated the gelatinase activities 
of MMP-9 induced in the calvaria tissues receiving sRANKL/LPS injection. Total MMP-9 
protein was similarly increased in the calvaria tissues, irrespective of Dox administration. 
These data indicated that systemic Dox administration can inhibit the RANKL-mediated in 
vivo osteoclastogenesis accompanied by reduced MMP-9 activities. These results, in turn, 
supported the in vitro findings that Dox inhibits sRANKL-mediated osteoclastogenesis, as 
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well as MMP-9 activities, while allowing the expression of MMP-9 protein expression in 
TRAP+ mononuclear cells (Fig. 5 F). 
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Fig. 5. Influence of Dox on the in vivo osteoclastogenesis induced in mouse calvaria 
tissues. After ten days of supra-calvaria injections with a combination of sRANKL (5 
μg/ml) and LPS (500 μg/ml), or control PBS for three consecutive days, calvaria tissues 
were decalcified and stained for TRAP. sRANKL/LPS-injected groups received systemic 
Dox administration (30mg/kg/day) or placebo PBS for 10 consecutive days. Histochemical 
results of calvaria tissues stained for TRAP are shown: A) control PBS injection, B) 
sRANKL/LPS injection and C) sRANKL/LPS injection and systemic administration with 
Dox (20x magnification; arrows indicate TRAP+ cells). TRAP enzyme activities in the 
calvaria tissue homogenates from 10-day-old samples were determined (D). *Significantly 
higher than control PBS placebo injection by Student’s t test (p<0.05). Using identical 
samples of calvaria tissue homogenates, gelatin gel Zymography (E) and Western blot for 
MMP-9 (F) were carried out, respectively. Mature MMP-9 (MW 86 kD) is indicated by 
arrow in the zymogram gel. 
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Systemic administration of Dox shows no effects on systemic bone mineral density  
Since Dox could inhibit in vivo RANKL-mediated osteoclastogenesis, the 
influence of Dox on homeostatic bone remodeling was examined (Fig. 6). Normal male 
BALB/c mice were treated with Dox or control water for 30 days. Bone mineral density 
(BMD) of whole body or femur measured on Day 30 did not show any significant 
differences between Dox-treated mice and control mice, indicating that Dox does not 
influence systemic physiologic bone metabolism during a time period of less than 30 days. 
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Fig. 6. Influence of Dox on systemic bone mineral density of mice. BALB/c mice (8-
week-old males, n = 5 mice/group) were treated with either Dox (30mg/kg/day in water 
solution) or with control water for 30 days (p.o. every single day). Afterwards, the animals 
were sacrificed, and the measurement of BMD (g/cm2) of whole body and femur was 
performed using PIXImusTM bone mineral densitometer (Lunar Corp., Madison, WI). The 
group treated with Dox did not show any statistically significant difference compared to the 
control placebo group receiving PBS. 
 
Modulation of c-Myc expression by Dox. 
RANKL ligation to its receptor (RANK) elicits the ubiquitination of the 
signaling adaptor molecule, TNF receptor-associated factor 6 (TRAF6), which transduces 
the activation signals through NF-kB and MAPK pathways. Such activation signals induce 
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the expression of transcription factors required for osteoclast differentiation, including c-
Fos, c-Myc and nuclear factor of activated T-cells c1 (NFATc1) (1, 23, 31, 33, 35). In order 
to examine the effects of Dox on the signaling pathways during RANKL-mediated 
osteoclastogenesis, the phosphorylation of MAPK pathway molecules, including p38, ERK 
and JNK, were examined by Western blot analysis (Fig.7 A). However, phosphorylation of 
these three molecules in RAW264.7 cells upon activation by RANKL was not affected by 
the presence of Dox, indicating that Dox affects either the downstream signaling of these 
three key molecules or other signaling pathways that are cooperative to MAPKs in 
RANKL-mediated osteoclastogenesis, such as Ca2+/Calcineurin or NF-kB pathways. 
RT-PCR analysis, as shown in Fig. 7B, demonstrates that Dox down-regulated 
c-Myc and mRNA expressions, as well as cathepsin K and TRAP. These translated proteins 
play key functional roles in the mature osteoclasts. Importantly, c-Myc is required in the 
up-regulation of mRNA expression of cathepsin K and TRAP during osteoclast 
differentiation (1). Therefore, the Dox-mediated, down-regulated mRNA expression of 
cathepsin K and TRAP appeared to be associated with the diminished expression of c-Myc 
in RANKL-stimulated RAW264.7 cells. These data indicate that the inhibitory effects of 
Dox on RANKL-mediated osteoclastogenesis are, at the very least, attributed to its 
suppression of c-Myc gene expression. To confirm if Dox suppresses c-Myc during 
RANKL-mediated osteoclastogenesis, focused gene expression arrays were employed. The 
results revealed that Dox did suppress the gene expression of c-Myc in RAW264.7 cells 
upon stimulation with sRANKL, whereas Dox did not suppress gene expression of c-Fos, 
which was also increased by RANKL stimulation in RAW264.7 cells (data not shown). 
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Fig 7. Effects of Dox on the phosphorylation of p38, ERK and JNK-MAPK and 
mRNA expression of c-Myc by RANKL-stimulated RAW264.7 cells. (A) Western blot 
for MAPK was carried out for p38-, ERK-, JNK-MAPK. The left hand panel shows kinetic 
experiments performed from 5-30 min after stimulation with sRANKL (50 ng/ml). Results 
of RAW264.7 cells stimulated with sRANKL (50 ng/ml) in the presence or absence of Dox 
(2 µg/ml) for 30 min are shown in right hand panel. (B) RT-PCR for mRNA of c-Myc; 
cathepsin K, TRAP and β-actin of RAW264.7 cells stimulated with sRANKL for 48 h. (B1) 
negative control; (B2) sRANKL (50 ng/ml); (B3) sRANKL with Dox (2 μg/ml).  
 
 
Discussion                                                                                                                                                              
The growing use of Dox in clinical practice is due to its inhibitory activity 
against MMPs in addition to its antibiotic activity. Although Dox is thought to inhibit bone 
resorption primarily through its ability to inhibit MMPs (8, 28), its direct influence on 
sRANKL-mediated osteoclastogenesis has been unclear. In the present study, however, our 
results demonstrate that Dox can inhibit both in vitro and in vivo RANKL-mediated 
osteoclastogenesis in association with its suppression of c-Myc gene expression. Moreover, 
the present study showed that the inhibitory effects of Dox in RANKL-mediated 
osteoclastogenesis, while unrelated to the presence of any Dox toxicity, do, in fact, result 
from both the blocking of MMP-9 enzyme activity and suppression of osteoclast 
differentiation, especially the multinucleation process from TRAP+ pre-osteoclast cells.  
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Our results further demonstrated that Dox down-regulated the expression of c-
Myc mRNA along with the diminished mRNA expression for TRAP and cathepsin K (Fig. 
7 B), as well as TRAP activity (Fig. 4 A), while Dox lacks such inhibitory effects on MMP-
9 protein expression (Fig. 4  B). These results were supported by the study of Battaglino et 
al. (1) who found that expression of c-Myc, a transcription factor, is up-regulated in 
response to sRANKL and is required for osteoclast differentiation. They demonstrated this 
by the introduction of dominant negative c-Myc expression in RAW264.7 cells which show 
remarkably reduced RNA expressions for TRAP and cathepsin K upon stimulation with 
RANKL (1). Therefore, it is plausible that the Dox-mediated suppression of TRAP and 
cathepsin K mRNA expression found in the present study may be due to the c-Myc down-
regulation induced by Dox.  
Three enzymes, including TRAP, cathepsin K and MMP-9, are all considered 
functional phenotypic markers for mature osteoclasts. As such, the expression of all three 
molecules plays important, but different, roles in osteoclast bone resorption activity (17, 
44). TRAP is engaged in bone destruction by dephosphorylation of noncollagenous matrix 
proteins in the bone. Cathepsin K functions in solubilization of hydroxyapatite crystals in 
the bone that results in exposure of the collagenous bone matrix, creating resorption 
lacunae after collagen degradation. MMP-9 degrades collagen types I, III, IV, and V, as 
well as gelatins. Therefore, MMP-9 produced by osteoclasts plays a pivotal role in 
digesting collagen types I, III and IV, which are present in the bone. Importantly, then, the 
inhibitory function of Dox on mRNA expression for cathepsin K and TRAP, accompanied 
by suppression of MMP-9 enzyme activity strongly appears to be responsible for the 
diminished pit formation activity by RANKL-stimulated RAW264.7 cells (Fig. 2 I). 
A number of molecular mechanisms underlying the differentiation, function, 
and survival of osteoclasts have been elucidated in the last few years (16, 34, 36, 41). 
Holmes et al. (11) showed that Dox can reduce osteoclast differentiation induced from 
human peripheral blood mononuclear cells (PBMC) upon stimulation with sRANKL and 
M-CSF. They also demonstrated that Dox at lower concentrations (ranging between 0.25 to 
2.5 μg/ml), which are similar to the ranges of Dox used in the present study, reduces 
osteoclast formation without induction of apoptosis in PBMC stimulated with sRANKL 
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and M-CSF, while higher concentrations of Dox, those of more than 5 μg/ml, induce 
apoptosis in maturely differentiated osteoclast cells (11). This supports the present study in 
which we hypothesize that Dox inhibits osteoclastogenesis independent of its toxic effects 
inducing cell death. We demonstrated that Dox was not toxic to RAW264.7 cells or bone 
marrow cells, irrespective of RANKL stimulation. Furthermore, the results of DNA array 
analysis for RAW264.7 cells showed that Dox suppressed one of the apoptosis induction 
genes, Bax, induced by RANKL stimulation (data not shown). Additionally, the present 
study appeared to show that the inhibitory effects of Dox on sRANKL-mediated 
osteoclastogenesis are partly attributable to the inhibition of c-Myc gene expression (Fig. 7) 
and not to the induction of cell death (Fig.3). It is, however, still to be elucidated which 
molecule is the direct target of Dox that results in the inhibition of c-Myc gene expression, 
as well as cathepsin K and TRAP mRNA, in the RANKL-mediated osteoclastogenesis. 
Excessive MMP activity, with particular reference to collagenase and/or 
gelatinase, has been noted in many disease processes, including rheumatoid and 
osteoarthritis, metastatic cancer, aneurysm, adult periodontitis, osteoporosis, corneal 
abrasion, and others (20). Specifically, with respect to periodontitis, it has been reported 
that MMPI can inhibit alveolar bone loss induced by local LPS injection in a rat model of 
experimental periodontal disease (24). Interestingly, although Dox did not affect the 
expression of MMP-9 protein in RAW264.7 cells and calvaria tissue upon stimulation with 
RANKL, gelatinase activity of MMP-9 in RAW264.7 cells and calvaria tissues was, in fact, 
remarkably decreased by Dox. The inhibition of this activity is most likely due to the 
pharmacological action of Dox, which binds to the primary and secondary zinc and calcium 
ions within the catalytic domain of the MMP (7). Therefore, a decreased activity of MMP-9 
would lead to a reduction in both connective tissue degradation and bone resorption, which 
are key events involved in the pathogenesis of osteoarthritis, periodontitis, and other 
diseases (5, 19, 24). It is true that MMP-9 is produced not only by osteoclast cells, but also 
by fibroblasts (10) that comprise the major cellular populations in connective tissues. 
Therefore, inhibition of MMP-9 by Dox most likely protects both hard and soft tissues from 
destruction.  
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Finally, Dox administered orally (30mg/kg/day for 30 days) did not 
physiologically interfere with BMD during the entire 30 days of systemic administration, 
while the same dose of Dox did inhibit the osteoclastogenesis induced within 10 days after 
RANKL injection of calvaria tissues. Brandt et al. studied the effects of Dox on 431 women 
with unilateral osteoarthritis of the knee (3). They reported that, after 30 months of 
treatment following a regimen of doxycycline, patients experienced reduced progression of 
minimum joint space width (JSW) in the index knee compared to the placebo group, 
whereas JSW of the contralateral knee was not affected by Dox treatment (3). They 
concluded that pathogenic mechanisms in the contralateral knee joint were different from 
those in the index knee. Since, even in the same knee lesion, the mechanism of bone 
destruction differs, it is conceivable that the mechanism underlying local inflammatory 
bone resorption would be different from that of systemic bone resorption in homeostatic 
bone remodeling. Although Dox treatment in the present study did not affect systemic 
BMD within 30 days, it could, however, affect BMD in long-term administration. This 
hypothesis is supported by a study which shows that an 8-week administration of 
minocycline (a Dox family agent) prevents the decrease of BMD in ovariectomized rats 
(42). To summarize, treating infectious inflammatory bone loss diseases with Dox may be 
additionally advantageous in that only bone resorption at the site of the inflamed lesion is 
affected, while systemic BMD remains unaffected by Dox.  
In conclusion, the present study indicated that the efficacy of Dox in the 
amelioration of infectious inflammatory bone loss lesion seems to involve novel bio-effects 
of Dox which inhibit RANKL-mediated osteoclastogenesis, in addition to its previously 
known effects as an antibiotic and as an MMP suppressor. 
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3. CONCLUSÃO 
 
1- Os resultados da análise dos índices PK/PD sugerem que uma dose inicial maior do que 
100 mg poderia resultar em melhores resultados clínicos.  
 
2- Os resultados referentes ao efeito da Dox sobre a MMP demonstraram que embora a 
Dox não interfira na produção desta enzima, a atividade da MMP foi significantemente 
diminuída na presença deste fármaco;  
 
3- A eficácia clínica observada da Dox, quando de seu emprego como modulador da 
atividade do hospedeiro, parece não se limitar à inativação da MMP, mas estar relacionada 
também, a propriedades adicionais deste fármaco sobre os processos de osteoclastogênese e 
ativação osteoclástica mediada por RANKL, incluindo a modulação da expressão de c-
Myc, TRAP e Catepsina K. 
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